San Pedro (Huachuma)
San Pedro Cactus / Huachuma (Trichocereus / Echinopsis pachanoi)
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
Modern controlled human evidence is minimal and does not yet support any clinical claim. The strongest data come from a small set of healthy-subject pharmacology studies of isolated mescaline, principally a 2024 Basel double-blind, placebo-controlled crossover (Klaiber, Liechti and colleagues, roughly 16 healthy volunteers) characterizing dose-response, safety, and receptor mechanism. That study describes acute effects and tolerability, not treatment of any disorder. The remaining literature on mental-health benefit is observational: a 2021 naturalistic survey (Agin-Liebes and colleagues, 452 self-selecting mescaline users) in which most respondents with prior depression or anxiety reported self-rated improvement, a design vulnerable to recall and selection bias with no control group. For San Pedro specifically, as a whole-cactus ceremonial preparation, there are no completed randomized controlled trials in patients. The honest reading is grade 1: a coherent mechanistic rationale and centuries of practitioner observation, with controlled clinical evidence still essentially absent, partly because legal scheduling has long suppressed the research.
Reference only. Not medical advice.
What can go wrong
Mescaline raises blood pressure, heart rate, and body temperature and commonly produces strong nausea and vomiting, which is culturally framed as purging but is physically taxing; it is hazardous for people with cardiovascular disease. Set, setting, and dose are difficult to control with whole-plant material of variable potency. Acute psychological distress, disorientation, and the precipitation or worsening of psychosis are documented risks of serotonergic psychedelics, and interactions with serotonergic medications including MAOIs and SSRIs are a concern. This is not a self-care practice; anyone considering it for a mental-health, addiction, or eating-related condition should work through a qualified clinician.
This is something to take to a clinician. The Atlas can tell you what is known about san pedro (huachuma) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
San Pedro, called huachuma or wachuma in its Andean homeland, is a tall columnar cactus of the genus Trichocereus (also classed as Echinopsis), most famously Echinopsis pachanoi, that contains the psychedelic alkaloid mescaline. Its ceremonial use is one of the oldest documented psychedelic traditions in the Americas, depicted in stone at Chavin de Huantar around 1300 to 1000 BCE and carried into the curanderismo of northern Peru, where maestros use it in all-night mesa ceremonies for healing, cleansing, and divination. Proponents and a growing number of psychedelic researchers describe potential for depression, anxiety, and substance-use disorders, and the first modern controlled studies of isolated mescaline are now underway, led from Basel. Those studies so far are healthy-subject pharmacology, not patient trials, and there are no completed randomized controlled trials of San Pedro itself for any condition. Enel records San Pedro as a deeply rooted ceremonial tradition with a plausible mechanism and very thin controlled evidence, set inside genuine cultural-sovereignty and legal complexity.
A mescaline-bearing Andean cactus carried in healing ceremony for more than three thousand years, now circling the edges of modern psychiatry with almost no controlled human trials to its name.
How it is supposed to work
Established pharmacology: the cactus contains mescaline (3,4,5-trimethoxyphenethylamine), a classic serotonergic psychedelic that acts primarily as a 5-HT2A receptor agonist. A 2024 double-blind study from a Basel research group reported that co-administering the 5-HT2A antagonist ketanserin strongly blunted mescaline's subjective and physiological effects, which the authors read as support for that receptor as the central pathway. Proposed and unproven: practitioners and some researchers describe lasting therapeutic benefit arising from acute "mystical-type" or self-transcendent experience plus the ceremonial container, a psychological and contextual mechanism that has not been isolated or tested for San Pedro in controlled patient trials. Whether any durable mental-health change is attributable to mescaline pharmacology, to ceremony and expectancy, or to both together is presently undetermined.
What people get wrong
Often saidSan Pedro is a proven natural treatment for depression and addiction.
ActuallyThere are no completed randomized controlled trials of San Pedro for any condition; benefit claims rest on practitioner reports and a self-selected user survey.
Often saidBecause the cactus is legal to buy, consuming it ceremonially is legal too.
ActuallyIn the United States the whole plant is generally legal as an ornamental, but extracting or ingesting it for its mescaline crosses into Schedule I territory.
Who profits, and who pushes back
Northern Peruvian curandero collectives
They describe huachuma as a living medicine of specific communities and warn that wild harvesting and foreign commercialization threaten both the cactus and the knowledge that surrounds it.
Matthias Liechti, University Hospital Basel
His group reports that mescaline produces dose-dependent effects through the 5-HT2A receptor and is investigating therapeutic potential, while stressing that controlled patient evidence does not yet exist.
Psychedelic therapy and retreat proponents
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
They promote San Pedro retreats for healing, trauma, and personal transformation, claims that outrun the controlled clinical evidence and carry direct financial interest.
Addiction and psychiatry clinicians
They note cardiovascular load, intense nausea, psychosis risk, and serotonergic drug interactions, and urge that anyone with a treatable condition work through qualified care rather than self-experiment.
Where the research comes from
Most of the published research on this comes from one place. 100% of it is from Peru (northern highlands and coast). Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Peru (northern highlands and coast) | 100% |
| Ecuador and Bolivia (Andean) | 55% |
| United States (retreat and research interest) | 45% |
| Western Europe | 35% |
| Australia | 25% |
How we got here
The oldest documented use traces to the Chavin culture of the northern Peruvian highlands, where a stone relief at Chavin de Huantar dated to roughly 1300 to 1000 BCE depicts a fanged figure clutching a ribbed San Pedro cactus, among the earliest clear records of a psychedelic ceremonial tradition anywhere in the Americas. From there the practice runs through Moche, Nazca, and later Andean peoples, woven into textiles and ceramics that show the cactus alongside felines, serpents, and spiral motifs. The living tradition today belongs to the curanderos and curanderas of northern Peru, centered on the sacred lagoons of Las Huaringas above Huancabamba and the herb markets of Chiclayo. The plant is known to these communities as huachuma or wachuma; "San Pedro" is a later colonial overlay, naming the cactus for Saint Peter and his keys to heaven. The Quechua and coastal healing systems, not any European source, define how it is grown, harvested, brewed, and held in ceremony.
San Pedro's documented history begins in the Andes, not in any Western source. The Chavin culture (roughly 1500 to 500 BCE) left the earliest clear depictions, including the carved huachumero figure at the temple of Chavin de Huantar, and later Andean peoples including the Moche and Nazca continued the imagery on ceramics and textiles. Through the Spanish colonial period the practice was suppressed as idolatry and the cactus acquired its Catholic name, San Pedro, yet ceremonial knowledge survived among coastal and highland healers. Western science isolated mescaline from peyote in 1897 (Arthur Heffter) and synthesized it in 1919 (Ernst Spath), and mid-twentieth-century figures such as Aldous Huxley and Humphry Osmond brought mescaline into wider Western attention, but global drug prohibition in the 1960s and 1970s largely halted clinical study. In November 2022 Peru declared the knowledge and traditional uses of San Pedro part of its Cultural Heritage of the Nation, a formal recognition of the northern curandero lineages.
- c. 1300 to 1000 BCEChavin de Huantar relief depicts a figure holding a San Pedro cactus, among the oldest documented psychedelic traditions in the Americas
- 1897 to 1919Heffter isolates mescaline from peyote (1897); Spath synthesizes it (1919)
- 1960s to 1970sGlobal drug prohibition schedules mescaline and largely halts clinical research
- 2021Agin-Liebes and colleagues publish a naturalistic survey of 452 mescaline users reporting self-rated psychiatric improvement
- 2022 to 2024Peru declares San Pedro knowledge Cultural Heritage of the Nation (2022); Basel team publishes controlled healthy-subject mescaline pharmacology (2024)
How it is understood
San Pedro is inseparable from the night-long mesa ceremony of Andean curanderismo, in which a maestro curandero arranges a ground altar of stones, shells, staffs, and images, sings icaros and tarjos, and uses the brew for diagnosis, cleansing (limpia), and divination rather than as a recreational substance. The whole arc of preparation, song, and aftercare is the practice; the alkaloid is only one part of it.
Where scholars disagree
San Pedro is a living ceremonial practice of northern Peruvian curanderos and curanderas, centered on Las Huaringas (Huancabamba) and the Chiclayo herb markets, and was declared Cultural Heritage of the Nation by Peru in 2022. Andean curandero collectives and allied advocates have raised concerns about wild-harvest pressure on the cactus, loss of traditional knowledge, and foreign retreat operators and companies commercializing the medicine and isolated mescaline without benefit-sharing or community consent. Treat this as an active sovereignty question, not a free commons.
Whether San Pedro and mescaline have genuine, durable therapeutic value for psychiatric conditions, or whether reported benefits reflect uncontrolled expectancy, ceremony, and selection effects, is unresolved because controlled patient data are essentially absent.
Psychedelic researchers and ceremony proponents
Mescaline shows a plausible serotonergic mechanism and observational signals of benefit for depression, anxiety, and substance use that they argue justify clinical development.
What it rests on2024 Basel healthy-subject pharmacology reporting a 5-HT2A mechanism and tolerability; 2021 naturalistic survey of 452 users reporting self-rated psychiatric improvement.
Conventional psychiatry and evidence reviewers
No completed randomized controlled trial in patients supports a therapeutic claim for San Pedro; current human benefit data are observational and confounded.
What it rests onAbsence of patient RCTs; reliance on self-selected survey samples with recall and selection bias and no placebo control.
This disagreement is live. It has not settled.
At a glance
- Active compound
- Mescaline, a 5-HT2A receptor agonist concentrated in the green outer flesh
- Oldest documented use
- Carved at Chavin de Huantar, northern Peru, c. 1300 to 1000 BCE
- Living tradition
- Northern Peruvian curanderismo; mesa ceremony at Las Huaringas and Chiclayo
- Controlled patient trials
- None completed for San Pedro; modern mescaline trials are healthy-subject pharmacology
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about San Pedro (Huachuma). A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.